Diamond, Jennifer R.
Goff, Barbara
Forster, Martin D.
Bendell, Johanna C.
Britten, Carolyn D.
Gordon, Michael S.
Gabra, Hani
Waterhouse, David M.
Poole, Mark
Ross Camidge, D.
Hamilton, Erika
Moore, Kathleen M.
Funding for this research was provided by:
MEI Pharma, Inc.
Article History
Received: 16 February 2017
Accepted: 20 February 2017
First Online: 10 March 2017
Compliance with ethical standards
: This study was conducted according to ICH guidelines and all sites had IRB/EC approval prior to enrolling patients.
: This study was funded by MEI Pharma, Inc.
: Jennifer R. Diamond, Barbara Goff, Carolyn D. Britten, Michael S. Gordon, Hani Gabra, David M. Waterhouse, D. Ross Camidge, and Erika P. Hamilton report no potential conflict of interest. Mark Poole is an employee of MEI Pharma. Kathleen M. Moore reports advisory boards for: Astra Zeneca, Advaxis, Clovis, Immunogen, Genentech/Roche and VBL Therapeutics, and Steering Committees for: Advaxis and Astra Zeneca. Johanna C. Bendell reports research funding from Gilead, Genentech, BMS, Five Prime, Lilly, Merck, Medimmune, Celgene, EMD Serono, Taiho, Macrogenetics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, Astrazeneca, BI, Baiichi Sankyo, Bayer, Incyte, Apexigen, Roche, Koltan, SynDevRx, Forty Seven, Abbvie, StemCentrix, Array, Agios, ARMO, and CytoMx.
: All participants gave their informed consent in writing prior to inclusion in the study.